Biochemical and structural characterization of alanine racemase from Bacillus anthracis (Ames)

BMC Structural Biology

Volumn 9, Issue , 2009, Pages

  Couñago, Rafael M ^a   Davlieva, Milya ^b   Strych, Ulrich ^c   Hill, Ryan E ^a   Krause, Kurt L ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b RICE UNIVERSITY   (United States)

^c University of Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70349602115     PISSN: None     EISSN: 14726807     Source Type: Journal    
DOI: 10.1186/1472-6807-9-53     Document Type: Article

References (63)

1. Anthrax. TC Dixon M Meselson J Guillemin PC Hanna, N Engl J Med 1999 341 11 815 826 10.1056/NEJM199909093411107 10477781
2. Bacillus anthracis aerosols in goat hair processing mills. CM Dahlgren LM Buchanan HM Decker SW Freed CR Phillips PS Brachman, Am J Hyg 1960 72 24 31 13813720
3. The Sverdlovsk anthrax outbreak of 1979. M Meselson J Guillemin M Hugh-Jones A Langmuir I Popova A Shelokov O Yampolskaya, Science 1994 266 5188 1202 1208 10.1126/science.7973702 7973702
4. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). CDC, MMWR 2000 49 RR15 1 20
5. Bioterrorism - types of epidemics, new epidemiological paradigm and levels of prevention. V Radosavljevic B Jakovljevic, Public Health 2007 121 7 549 557 10.1016/j.puhe.2006.12.010 17481679
6. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. JA Jernigan DS Stephens DA Ashford C Omenaca MS Topiel M Galbraith M Tapper TL Fisk S Zaki T Popovic, et al. Emerg Infect Dis 2001 7 6 933 944 11747719
7. Comparative genome sequencing for discovery of novel polymorphisms in Bacillus anthracis. TD Read SL Salzberg M Pop M Shumway L Umayam L Jiang E Holtzapple JD Busch KL Smith JM Schupp, et al. Science 2002 296 5575 2028 2033 10.1126/science.1071837 12004073
8. Mechanism of D-cycloserine action: alanine racemase from Escherichia coli W. MP Lambert FC Neuhaus, J Bacteriol 1972 110 3 978 987 4555420
9. The potential use of mechanism-based enzyme inactivators in medicine. RB Silverman, J Enzyme Inhib 1988 2 2 73 90 10.3109/14756368809040714 3069967
10. Genes of Bacillus cereus and Bacillus anthracis encoding proteins of the exosporium. SJ Todd AJ Moir MJ Johnson A Moir, J Bacteriol 2003 185 11 3373 3378 10.1128/JB.185.11.3373-3378.2003 12754235
11. Factors affecting the germination of spores of Bacillus anthracis. RW Titball RJ Manchee, J Appl Bacteriol 1987 62 3 269 273 3110118
12. Effects of endogenous D-alanine synthesis and autoinhibition of Bacillus anthracis germination on in vitro and in vivo infections. MT McKevitt KM Bryant SM Shakir JL Larabee SR Blanke J Lovchik CR Lyons JD Ballard, Infect Immun 2007 75 12 5726 5734 10.1128/IAI.00727-07 17923523
13. Proteomic profiling and identification of immunodominant spore antigens of Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis. VG Delvecchio JP Connolly TG Alefantis A Walz MA Quan G Patra JM Ashton JT Whittington RD Chafin X Liang, et al. Appl Environ Microbiol 2006 72 9 6355 6363 10.1128/AEM.00455-06 16957262
14. Identification of Bacillus anthracis proteins associated with germination and early outgrowth by proteomic profiling of anthrax spores. CM Huang KW Foster TS DeSilva KR Van Kampen CA Elmets DC Tang, Proteomics 2004 4 9 2653 2661 10.1002/pmic.200400831 15352240
15. Three Dimensional Structure-Aided Drug Design. B Veerapandian, Burger's Medicinal Chemistry and Drug Discovery New York, New York: John Wiley & Sons, Inc., Wolff ME, 5 1995 1 303 348
16. Structure-based drug design: computational advances. TJ Marrone JM Briggs JA McCammon, Annu Rev Pharmacol Toxicol 1997 37 71 90 10.1146/annurev.pharmtox. 37.1.71 9131247
17. Structure-based drug design. TL Blundell, Nature 1996 384 Supp 23 26 8895597
18. Benchmarking B cell epitope prediction: underperformance of existing methods. MJ Blythe DR Flower, Protein Sci 2005 14 1 246 248 10.1110/ps.041059505 15576553
19. Crystal structure of the malaria vaccine candidate apical membrane antigen 1. JC Pizarro B Vulliez-Le Normand ML Chesne-Seck CR Collins C Withers-Martinez F Hackett MJ Blackman BW Faber EJ Remarque CH Kocken, et al. Science 2005 308 5720 408 411 10.1126/science.1107449 15731407
20. Structural basis for the EBA-175 erythrocyte invasion pathway of the malaria parasite Plasmodium falciparum. NH Tolia EJ Enemark BK Sim L Joshua-Tor, Cell 2005 122 2 183 193 10.1016/j.cell.2005.05.033 16051144
21. Structure of a Michaelis complex analogue: propionate binds in the substrate carboxylate site of alanine racemase. AA Morollo GA Petsko D Ringe, Biochemistry 1999 38 11 3293 3301 10.1021/bi9822729 10079072
22. Determination of the structure of alanine racemase from Bacillus stearothermophilus at 1.9 resolution. JP Shaw GA Petsko D Ringe, Biochemistry 1997 36 6 1329 1342 10.1021/bi961856c 9063881
23. Crystal structure at 1.45 resolution of alanine racemase from a pathogenic bacterium, Pseudomonas aeruginosa, contains both internal and external aldimine forms. P LeMagueres H Im A Dvorak U Strych M Benedik KL Krause, Biochemistry 2003 42 50 14752 14761 10.1021/bi030165v 14674749
24. A side reaction of alanine racemase: transamination of cycloserine. TD Fenn GF Stamper AA Morollo D Ringe, Biochemistry 2003 42 19 5775 5783 10.1021/bi027022d 12741835
25. Reaction of alanine racemase with 1-aminoethylphosphonic acid forms a stable external aldimine. GF Stamper AA Morollo D Ringe, Biochemistry 1998 37 29 10438 10445 10.1021/bi980692s 9671513
26. The 1.9 crystal structure of alanine racemase from Mycobacterium tuberculosis contains a conserved entryway into the active site. P LeMagueres H Im J Ebalunode U Strych MJ Benedik JM Briggs H Kohn KL Krause, Biochemistry 2005 44 5 1471 1481 10.1021/bi0486583 15683232
27. Structural evidence that alanine racemase from a D-cycloserine-producing microorganism exhibits resistance to its own product. M Noda Y Matoba T Kumagai M Sugiyama, J Biol Chem 2004 279 44 46153 46161 10.1074/jbc.M404605200 15302886
28. Structures of an alanine racemase from Bacillus anthracis (BA0252) in the presence and absence of (R)-1-aminoethylphosphonic acid (L-Ala-P). K Au J Ren TS Walter K Harlos JE Nettleship RJ Owens DI Stuart RM Esnouf, Acta Crystallogr Sect F Struct Biol Cryst Commun 2008 64 Pt 5 327 333 10.1107/S1744309108007252 18453697
29. Crystallization and improvement of crystal quality for x-ray diffraction of maltooligosyl trehalose synthase by reductive methylation of lysine residues. M Kobayashi M Kubota Y Matsuura, Acta Crystallogr D Biol Crystallogr 1999 55 Pt 4 931 933 10.1107/S0907444999002115 10089339
30. X-ray crystallographic analysis of pokeweed antiviral protein-II after reductive methylation of lysine residues. IV Kurinov C Mao JD Irvin FM Uckun, Biochem Biophys Res Commun 2000 275 2 549 552 10.1006/bbrc.2000.3329 10964701
31. Three-dimensional structure of myosin subfragment-1: a molecular motor. I Rayment WR Rypniewski K Schmidt-Base R Smith DR Tomchick MM Benning DA Winkelmann G Wesenberg HM Holden, Science 1993 261 5117 50 58 10.1126/science.8316857 8316857
32. The essential mosquito-stage P25 and P28 proteins from Plasmodium form tile-like triangular prisms. AK Saxena K Singh HP Su MM Klein AW Stowers AJ Saul CA Long DN Garboczi, Nat Struct Mol Biol 2006 13 1 90 91 10.1038/nsmb1024 16327807
33. A pivotal role for reductive methylation in the de novo crystallization of a ternary complex composed of Yersinia pestis virulence factors YopN, SycN and YscB. FD Schubot DS Waugh, Acta Crystallogr D Biol Crystallogr 2004 60 Pt 11 1981 1986 10.1107/S0907444904023005 15502305
34. Lysine methylation as a routine rescue strategy for protein crystallization. TS Walter C Meier R Assenberg KF Au J Ren A Verma JE Nettleship RJ Owens DI Stuart JM Grimes, Structure 2006 14 11 1617 1622 10.1016/j.str.2006.09.005 17098187
35. Large-scale evaluation of protein reductive methylation for improving protein crystallization. Y Kim P Quartey H Li L Volkart C Hatzos C Chang B Nocek M Cuff J Osipiuk K Tan, et al. Nat Methods 2008 5 10 853 854 10.1038/nmeth1008-853 18825126
36. The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria. TD Read SN Peterson N Tourasse LW Baillie IT Paulsen KE Nelson H Tettelin DE Fouts JA Eisen SR Gill, et al. Nature 2003 423 6935 81 86 10.1038/nature01586 12721629
37. Proteomics reveals that proteins expressed during the early stage of Bacillus anthracis infection are potential targets for the development of vaccines and drugs. CM Huang CA Elmets DC Tang F Li N Yusuf, Genomics Proteomics Bioinformatics 2004 2 3 143 151 15862115
38. Characterization of the alanine racemases from two mycobacteria. U Strych RL Penland M Jimenez KL Krause MJ Benedik, FEMS Microbiol Lett 2001 196 2 93 98 10.1111/j.1574-6968.2001.tb10547.x 11267762
39. Thermostable alanine racemase from Bacillus stearothermophilus: molecular cloning of the gene, enzyme purification, and characterization. K Inagaki K Tanizawa B Badet CT Walsh H Tanaka K Soda, Biochemistry 1986 25 11 3268 3274 10.1021/bi00359a028 3015202
40. Characterization of the alanine racemases from Pseudomonas aeruginosa PAO1. U Strych HC Huang KL Krause MJ Benedik, Curr Microbiol 2000 41 4 290 294 10.1007/s002840010136 10977898
41. Mutant analysis shows that alanine racemases from Pseudomonas aeruginosa and Escherichia coli are dimeric. U Strych MJ Benedik, J Bacteriol 2002 184 15 4321 4325 10.1128/JB.184.15.4321-4325.2002 12107154
42. Dimeric Inhibitors of HIV-1 Protease. N Boggetto M Reboud-Ravaux, Biol Chem 2002 383 9 1321 1324 10.1515/BC.2002.150 12437124
43. Design and Synthesis of New Inhibitors of HIV-1 Protease Dimerization with Conformationally Constrained Templates. M Song S Rajesh Y Hayashi Y Kiso, Bioorg Med Chem Lett 2001 11 18 2465 2468 10.1016/S0960-894X(01)00468-1 11549448
44. Breaking the spell: drug discovery based on modulating protein-protein interactions. AD Strosberg, Expert Rev Proteomics 2004 1 2 141 143 10.1586/14789450.1.2.141 15966807
45. Residues Asp164 and Glu165 at the substrate entryway function potently in substrate orientation of alanine racemase from E. coli: Enzymatic characterization with crystal structure analysis. D Wu T Hu L Zhang J Chen J Du J Ding H Jiang X Shen, Protein Sci 2008 17 6 1066 1076 10.1110/ps.083495908 18434499
46. Application of high-throughput technologies to a structural proteomics-type analysis of Bacillus anthracis. K Au NS Berrow E Blagova IW Boucher MP Boyle JA Brannigan LG Carter T Dierks G Folkers R Grenha, et al. Acta Crystallogr D Biol Crystallogr 2006 62 Pt 10 1267 1275 10.1107/ S0907444906033555 17001104
47. Reductive methylation to improve crystallization of the putative oxidoreductase Rv0765c from Mycobacterium tuberculosis. W Rauert AN Eddine SH Kaufmann MS Weiss R Janowski, Acta Crystallogr Sect F Struct Biol Cryst Commun 2007 63 Pt 6 507 511 10.1107/S1744309107022506 17554174
48. Structural consequences of reductive methylation of lysine residues in hen egg white lysozyme: an X-ray analysis at 1.8-A resolution. WR Rypniewski HM Holden I Rayment, Biochemistry 1993 32 37 9851 9858 10.1021/bi00088a041 8373783
49. Purification and preliminary crystallization of alanine racemase from Streptococcus pneumoniae. U Strych M Davlieva JP Longtin EL Murphy H Im MJ Benedik KL Krause, BMC Microbiol 2007 7 40 10.1186/1471-2180-7-40 17509154
50. Sparse matrix sampling: a screening method for crystallization of proteins. J Jancarik S-H Kim, J Appl Crystallogr 1991 24 409 411 10.1107/S0021889891004430 (Pubitemid 21679358)
51. Recent changes to the MOSFLM package for processing film and image plate data. AGW Leslie, Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography 1992 26 27 33
52. SCALA, version 3.1.9. PR Evans, Medical Research Council Laboratory of Molecular Biology, Cambridge, UK 1993
53. The CCP4 suite: programs for protein crystallography. CCP4 suite, Acta Crystallogr D Biol Crystallogr 1994 50 Pt 5 760 763 15299374
54. MOLREP: an automated program for molecular replacement. A Vagin A Teplyakov, J Appl Cryst 1997 30 1022 1025 10.1107/S0021889897006766
55. Solvent Content of Protein Crystals. BW Matthews, J Mol Biol 1968 33 491 497 10.1016/0022-2836(68)90205-2 5700707
56. Coot: model-building tools for molecular graphics. P Emsley K Cowtan, Acta Crystallogr D Biol Crystallogr 2004 60 Pt 12 Pt 1 2126 2132 10.1107/S0907444904019158 15572765
57. Refinement of macromolecular structures by the maximum-likelihood method. GN Murshudov AA Vagin EJ Dodson, Acta Crystallogr D Biol Crystallogr 1997 53 Pt 3 240 255 10.1107/S0907444996012255 15299926
58. On the rigid-body motion of molecules in crystals. V Schomaker KN Trueblood, Acta Cryst, Section B 1968 24 1 63 76 10.1107/S0567740868001718
59. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. E Krissinel K Henrick, Acta Crystallogr D Biol Crystallogr 2004 60 Pt 12 Pt 1 2256 2268 10.1107/S0907444904026460 15572779
60. Inference of macromolecular assemblies from crystalline state. E Krissinel K Henrick, J Mol Biol 2007 372 3 774 797 10.1016/j.jmb.2007.05.022 17681537
61. WHAT IF: a molecular modeling and drug design program. G Vriend, J Mol Graph 1990 8 1 52 56 29. 10.1016/0263-7855(90)80070-V 2268628
62. Homology modeling, model and software evaluation: three related resources. R Rodriguez G Chinea N Lopez T Pons G Vriend, CABIOS 1998 14 523 528
63. 3DCoffee: combining protein sequences and structures within multiple sequence alignments. O O'Sullivan K Suhre C Abergel DG Higgins C Notredame, J Mol Biol 2004 340 2 385 395 10.1016/j.jmb.2004.04.058 15201059 (Pubitemid 38759917)